Specialised Therapeutics Expands Minjuvi Access in Australia
Singapore, August 2, 2026 Specialised Therapeutics (ST) announced that Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Singapore, August 2, 2026 Specialised Therapeutics (ST) announced that Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been...
Taipei, August 3, 2026 GlycoNex Inc. announced that the first patient has been successfully dosed in the first-in-human Phase...
San Francisco, August 3, 2026 AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. announced the initiation of patient dosing...
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
